High Content Screening Trends

Print Email to a friend

Highlights of this Report:

  • The main survey looked at the extent to which HCS instruments have been deployed; interest to acquire new HCS systems; which research groups are planning to use HCS; where and for which applications HCS is currently being applied in drug discovery; instrumentation preferences for HCS; live-cell imaging requirements; HCS informatics; future trends, limitations and unmet needs in HCS. In addition, a survey supplement documents user perceptions of HCS instrument manufacturers and HCS purchasing preferences/decision factors.

  • The main survey collected 75 responses (66 complete and 9 partially filled out) from 42 different Pharma/Biotech/CRO companies and 20 University/Research Institutes. The survey supplement collected 47 responses from 32 different Pharma/Biotech/CRO companies and 10 University/Research Institutes.

  • Responses from Pharma/Biotech/CRO were split geographically 57% North America and 43% Europe. Responses from University/Research Institutes were split geographically 95% North America and 5% Europe.

  • Survey respondents were either existing users of HCS systems or persons interested in applying HCS/purchasing HCS systems, and were drawn from 23 Large Pharma, 29 Small Pharma/Biotechs, 2 CROs and 20 University/Research Institute Labs. The job role/position of the majority of survey respondents was either Senior Scientist, Principal Investigator or Director.

  • Survey respondents represented 30 assay development and primary screening (HTS) labs, 6 therapeutic area labs, 5 secondary screening labs, 3 hits-to-leads (lead optimization) labs, 4 compound profiling labs, 2 leads-to-candidate labs, 4 other Pharma and Biotech lab functions and 21 University or Research labs.

  • Survey results were expressed as an average of all survey respondents. In addition, the data was fully reanalyzed after sub-division into the following survey groups: 1) Large Pharma; 2) Small Pharma/Biotech; 3) University/Research Institutes; 4) HCS Users; and 5) HCS Non-Users.

  • 51 HCS user labs (40 Pharma/Biotech/CR0 and 11 University/Research Institutes) responded to the survey and a total of 72 HCS instrument purchases (up to the end of 2004) were identified (53 units in Pharma/Biotech/CR0 and 19 units in University/Research Institutes). Cellomics ArrayScan® HCS reader was the most common instrument purchased.

  • 40 labs, many new to HCS (representing 31 Pharma/Biotech/CR0 and 9 University/Research Institutes) indicated they had budgeted or had plans to acquire an HCS instrument over the coming 3 years (2005 to 2007). Interest in the different HCS system brands was documented.

  • A model predicting the growth of instrument sales to the Pharma Market was developed. The model predicts sales of around 50 HCS systems/year in 2005 and 2006.

  • The breakdown of the HCS users operating budgets (excluding Capex purchases) was analyzed with bulk reagents (fluorescent probes and antibodies) representing the largest single item purchased.

  • On average labs involved in HCS plan 6.1 different HCS assays in 2005, with greatest interest from Oncology and Neurobiology research groups.

  • more...(PDF)
  • Further Information: http://www.selectbiosciences.com/marketreports/hcstrends.aspx